Literature DB >> 21680642

Proinflammatory and antiinflammatory cytokine levels in complicated and noncomplicated parapneumonic pleural effusions.

Evaldo Marchi1, Francisco S Vargas2, Milena M Acencio2, Rosa M S Sigrist3, Marjourie D A Biscaro3, Leila Antonangelo2, Lisete R Teixeira2, Richard W Light4.   

Abstract

OBJECTIVES: This study aimed to evaluate a panel of proinflammatory and antiinflammatory cytokines in noncomplicated and complicated parapneumonic pleural effusions and to correlate their levels with pleural fluid biochemical parameters.
METHODS: Serum and pleural effusion were collected from 60 patients with noncomplicated (n = 26) or complicated (n = 34) parapneumonic effusions and assayed for cytologic, biochemical, and proinflammatory and antiinflammatory cytokines. Student t test was used to compare serum and pleural fluid values, Spearman correlation to analyze the relationship between pleural fluid cytokines and biochemical parameters, and accuracy of pleural fluid cytokine levels to determine the optimal cutoff value for identification of complicated effusions. Corrections for multiple comparisons were applied and a P value < .05 was accepted as significant.
RESULTS: Serum and pleural fluid cytokine levels of IL-8, vascular endothelial growth factor (VEGF), IL-10, and tumor necrosis factor (TNF) soluble receptor (sR) II were similar between groups. In contrast, complicated effusions had higher levels of pleural fluid IL-1β, IL-1 receptor antagonist (ra), and TNF sRI. Negative correlations were found between pleural fluid glucose with IL-1β and TNF sRI and positive correlations between lactic dehydrogenate (LDH) with IL-1β, IL-8, and VEGF. Pleural fluid levels of IL-1β, IL-1ra, and TNF sRI were more accurate than IL-8, VEGF, IL-10, and TNF sRII in discriminating complicated effusions.
CONCLUSIONS: Both proinflammatory and antiinflammatory cytokine levels in pleural fluid are elevated in complicated in comparison with noncomplicated parapneumonic pleural effusions, and they correlate with both pleural fluid glucose and LDH levels. IL-1β, IL-1ra, and TNF sRI had higher sensitivity and specificity than IL-8, VEGF, IL-10, and TNF sRII in discriminating complicated effusions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680642     DOI: 10.1378/chest.10-3181

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Potential diagnostic value of serum/pleural fluid IL-31 levels for tuberculous pleural effusion.

Authors:  Yan Gao; Qinfang Ou; Jing Wu; Bingyan Zhang; Lei Shen; Shaolong Chen; Xinhua Weng; Ying Zhang; Wenhong Zhang; Lingyun Shao
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

2.  Proteome profiling reveals novel biomarkers to identify complicated parapneumonic effusions.

Authors:  Kuo-An Wu; Chih-Ching Wu; Chi-De Chen; Chi-Ming Chu; Li-Jane Shih; Yu-Ching Liu; Chih-Liang Wang; Hsi-Hsien Lin; Chia-Yu Yang
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

3.  Pleural cytokines MIF and MIP-3α as novel biomarkers for complicated parapneumonic effusions and empyema.

Authors:  Chia-Yu Yang; Yu-Hsuan Kuo; Min Chen; Chih-Liang Wang; Li-Jane Shih; Yu-Ching Liu; Pei-Chun Hsueh; Yi-Hsuan Lai; Chi-Ming Chu; Chih-Ching Wu; Kuo-An Wu
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

4.  Clinical importance of angiogenic cytokines, fibrinolytic activity and effusion size in parapneumonic effusions.

Authors:  Chi-Li Chung; Shih-Hsin Hsiao; George Hsiao; Joen-Rong Sheu; Wei-Lin Chen; Shi-Chuan Chang
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

5.  Diagnosis of infectious pleural effusion using predictive models based on pleural fluid biomarkers.

Authors:  Lucía Ferreiro; Óscar Lado-Baleato; Juan Suárez-Antelo; María Elena Toubes; María Esther San José; Adriana Lama; Nuria Rodríguez-Núñez; José Manuel Álvarez-Dobaño; Francisco J González-Barcala; Jorge Ricoy; Francisco Gude; Luis Valdés
Journal:  Ann Thorac Med       Date:  2019 Oct-Dec       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.